Cryptobiotix

Cryptobiotix

Foundation date

27/01/2021

Sector

#Biotechnology / R&D Services

Subsector

• #Therapeutics - Peptides
• #Therapeutics - Proteins
• #Therapeutics - Small molecules
• #Therapeutics - Vaccines
• #Other - Food
• #Other - Industrial Biotechnology
• #Other - Nutraceuticals
• #Pharma - Anti-infectives
• #Pharma - Gene therapy
• #Pharma - Generics
• #Pharma - Nucleic acid drugs
• #Pharma - Small molecule therapeutics
• #Pharma - Vaccines

Therapeutic areas

• #Cardiovascular
• #Conditions originating in the perinatal period
• #Digestive system
• #Neoplasms / cancer / oncology
• #Respiratory system
• #Skin and subcutaneous tissue

Cryptobiotix is a preclinical CRO providing insights into the gastrointestinal tract and gut microbiome. The validated, ex vivo SIFR® technology combines unmatched throughput and predictivity for clinical outcomes. Cryptobiotix offers research services to customers in the area of functional ingredients and therapeutic products, across foodtech, biotech and pharma. From early R&D screening to in-depth characterisation, they address specific research questions and provide answers to accelerate and de-risk gut health product development.